Melaxen 24's 3 mg coated tablets

The instruction for medical use of MELAKSEN medicine the Trade name Melaksen Mezhdunarodnoye the unlicensed name Is not present the Dosage form of the Tablet, coated, 3 mg Structure One tablet contains active agent - melatonin of 3 mg, excipients: calcium hydrophosphate, cellulose microcrystalline, magnesium stearate, structure of a cover: hydroksipropilmetiltsellyuloza, polyethyleneglycol, titan dioxide (E171). The description the Round, biconvex tablets coated from color, white to white with a yellowish shade, with dividing risky on one party. Pharmacotherapeutic group Hypnotic drugs and sedatives. Agonists of receptors of melatonin. Melatonin. The ATX N05CH01 code the Pharmacological Pharmacokinetics At properties intake is quickly and completely absorbed, easily passes through gistogematichesky barriers, including a blood-brain barrier. Melatonin is exposed to significant metabolism at primary passing through a liver (up to 60%) where there is its hydroxylation and conjugation to sulfate and a glucuronide with formation of a 6-sulfatoksimelatonin. Melatonin has short elimination half-life – 30-50 min. It is removed by kidneys in the form of metabolites. An insignificant part of melatonin (about 10%) is excreted in an invariable look. The pharmacodynamics Melatonin is the main hormone of an epiphysis. The main function of melatonin consists in processing of information on external illumination for the subsequent regulation of biological (daily) circadian rhythms. When lowering intensity of light stimulation of a retina of an eye the synthesis of melatonin increases, therefore, its maximum quantities is produced at night. The main physiological effect of melatonin is slowing down of secretion of gonadotrophins and, to a lesser extent, corticotropin, thyrotropin, Somatotropinum. Effects of melatonin are shown in its interaction with specific melatoninovy receptors (Mel IA, IB, IC). They are found in significant amounts in suprakhiazmatichesky kernels, in an eye retina, in a paraventrikulyarny kernel of a thalamus, a front hypothalamus, in gonads, in lymphocytes. Contributes to normalization of night sleep (accelerates backfilling, improves sleep quality, reduces number of night awakenings, improves health after morning awakening, does not cause a feeling of slackness, weakness and fatigue when awakening). Adapts an organism to fast change of time zones, reduces stressful reactions. Shows the immunostimulating and significant antioxidant properties. Does not cause accustoming and dependence. Indications - a sleep disorder, including at patients of advanced age are disorder of a normal day-night (circadian) rhythm the Route of administration and doses Inside. The adult on ½-1 tablet in 30-40 min. before going to bed once a day. Duration of treatment and repeated courses – according to the recommendation of the doctor. As an adaptogen when changing time zones: in 1 day prior to flight and in the next 2-5 days on 1 tablet in 30–40 minutes prior to a dream. The maximum daily dose up to 2 tablets a day (6 mg a day). Side effects − allergic reaction to drug components − hypostases in the first week of reception − a headache − nausea, vomiting, diarrhea − morning drowsiness of the Contraindication - hypersensitivity, allergic reactions - the profound renal failure, chronic kidney disease - autoimmune diseases - a leukosis, a lymphoma - a lymphogranulomatosis, a myeloma - epilepsy - diabetes of 1 type - pregnancy and the period of a lactation - the children's and teenage age up to 18 years Medicinal interactions Is incompatible with the MAO inhibitors, glucocorticosteroids, cyclosporine, acetylsalicylic acid, non-steroidal anti-inflammatory drugs, drugs oppressing activity of central nervous system. Special instructions At reception of Melaksena® it is necessary to avoid bright lighting. Pregnancy It is necessary to inform the women wishing to become pregnant on existence at drug of weak contraceptive action that is caused by influence of melatonin on a reproductive system. The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms during treatment needs to refrain from driving of transport and occupations potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions. Overdose Symptoms: strengthening of severity of side effects. Treatment: gastric lavage, symptomatic therapy. A form of release and packing On 12 tablets coated in blister strip packaging from a film of polyvinylchloride and aluminum foil. On 1 or 2 planimetric packs together with the instruction for medical use in the state and Russian languages place in a pack from cardboard. To Store storage conditions at a temperature of 10 - 30 °C, in the dry, protected from light place. To store out of children's reach! 4 years not to apply a period of storage after an expiration date. Prescription status Without prescription Unipharm Producer, INK., the USA the Owner of the registration certificate Unipharm, INK., the USA the Address of the organization accepting in the territory of the Republic, to the accepting complaint (offer) on quality of medicines from consumers Representation Unipharm, INK. (USA) in Republic of Kazakhstan Almaty, Nauryzbay St. of the batyr 17, office 106 the Organization responsible for post-registration observation of safety of medicine Representation Unipharm, INK. (USA) in Republic of Kazakhstan Almaty, Nauryzbay St. of the batyr 17, office 106